)
)
Dimerix Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Dimerix Limited
Access all reports
Dimerix Limited is an Australian biopharmaceutical company focused on developing new therapies for rare and progressive diseases, particularly kidney and inflammatory diseases. The company’s lead candidate targets chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease, using a proprietary drug discovery and development platform. Dimerix applies receptor-based science to create treatments that address unmet medical needs in complex diseases with few current therapeutic options. The company is involved in clinical trials to advance its drug candidates towards regulatory approval. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
DXB
Country
🇦🇺 Australia